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Rifaximin is a poorly absorbed semisynthetic antibiotic derivative of rifampin licensed for use in the
treatment of traveler’s diarrhea. Rifaximin reduces the symptoms of enteric infection, often without pathogen
eradication and with limited effects on intestinal flora. Epithelial cells (HEp-2 [laryngeal], HCT-8 [ileocecal],
A549 [lung], and HeLa [cervical]) were pretreated with rifaximin (or control antibiotics) prior to the addition
of enteroaggregative Escherichia coli (EAEC). EAEC adherence was significantly reduced following rifaximin
pretreatment compared to pretreatment with rifampin or doxycycline for three of the four cell lines tested. The
rifaximin-mediated changes to epithelial cells were explored further by testing the attachment and internal-
ization of either Bacillus anthracis or Shigella sonnei into A549 or HeLa cells, respectively. The attachment and
internalization of B. anthracis were significantly reduced following rifaximin pretreatment. In contrast, neither
the attachment nor the internalization of S. sonnei was affected by rifaximin pretreatment of HeLa cells,
suggesting that rifaximin-mediated modulation of host cell physiology affected bacteria utilizing distinct
attachment/internalization mechanisms differently. In addition, rifaximin pretreatment of HEp-2 cells led to
reduced concentrations of inflammatory cytokines from uninfected cells. The study provides evidence that
rifaximin-mediated changes in epithelial cell physiology are associated with changes in bacterial attachment/
internalization and reduced inflammatory cytokine release.
Rifaximin is a semisynthetic rifamycin derivative that has
been safely and successfully used to treat and prevent traveler’s
diarrhea (6, 7, 13, 26). Rifaximin’s additional pyridoimidazole
ring makes it virtually nonabsorbable (0.4%), leading to high
concentrations of the drug in feces after oral administration
(15). Rifaximin has also been used successfully in the treat-
ment of irritable bowel syndrome (9), infectious diarrhea (7,
8), small bowel bacterial overgrowth (29), hepatic encephalop-
athy (18, 19), pouchitis (7), and fulminant ulcerative colitis
(12). The mechanism(s) of action of rifaximin in these diverse
conditions remains poorly defined. Rifaximin has been shown
to have effects on gene-regulatory pathways in mammalian
cells (13, 14), suggesting that the drug may have effects on
mammalian cells independent of its antimicrobial properties.
Furthermore, rifaximin is a unique antibiotic in several ways:
(i) bacterial pathogens show a low potential for developing
resistance during rifaximin therapy, in contrast to the situation
with the structurally related drug rifampin (4); (ii) following
oral administration, the drug has little effect on Gram-negative
coliforms in the gut or on Gram-positive enterococcal flora (7,
8); (iii) the drug ameliorates diarrheal disease symptoms, often
without significant alteration to the intestinal pathogen burden
or the counts of intestinal flora (1, 7, 8), even though rifaximin
concentrations can reach 8,000 g/g of stool after 3 days of
treatment (15). These observations suggest the possibility that
some of the positive results of rifaximin treatment could be due
both to direct drug effects on the pathogen and to an effect on
intestinal cells, rendering them resistant to bacterial coloniza-
tion/internalization.
Since many pathogenic bacteria need to attach to or invade
host epithelial cells as a first step in the disease process, we
investigated the possibility that rifaximin could affect bacterial
attachment. Since enteroaggregative Escherichia coli (EAEC)
is phenotypically characterized by its “stacked-brick” adher-
ence pattern on HEp-2 cells, we tested the adherence of EAEC
strain O42 to rifaximin-pretreated HEp-2 (laryngeal) cells in
addition to examining its attachment to HCT-8 (ileocecal)
A549 (lung), or HeLa (cervical) cells pretreated with either
rifaximin, rifampin, doxycycline, or acetone (solvent control).
The data presented in this report demonstrate that rifaximin
pretreatment, but not pretreatment with controls, significantly
decreased EAEC attachment to HEp-2, A549, and HeLa cells,
suggesting that some of the beneficial effects of this drug are
due to modifications to the host cell epithelium and that dif-
ferent cell types respond differently to rifaximin treatment.
Rifaximin-mediated changes to host cells were also examined
in the context of different bacteria, i.e., we assessed the adher-
ence and internalization of either Bacillus anthracis or Shigella
sonnei into either A549 cells or HeLa cells, respectively (24,
25). These studies demonstrated that rifaximin pretreatment
had no effect on S. sonnei adherence or internalization but
significantly altered these parameters for B. anthracis. These
data suggest that rifaximin-mediated changes to epithelial cell
physiology do not affect all bacteria, i.e., the adherence mech-
anisms utilized by EAEC are very different from those used by
B. anthracis, and the type III secretory system utilized by S.
sonnei to gain access to epithelial cells is not found in B.
anthracis (23).
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MATERIALS AND METHODS
Bacterial strains and cell lines. EAEC strain O42 (provided by J. Nataro,
University of Maryland School of Medicine, Baltimore, MD) (20), S. sonnei (a
clinical isolate obtained from a patient in India by our laboratory in 2008), and
B. anthracis Sterne strain 7702 (provided by T. M. Koehler, University of Texas
Health Science Center, Houston, TX) were used in this study.
HEp-2 (a human larynx squamous cell carcinoma) (5, 12), HCT-8 (a human
intestinal adenocarcinoma cell line) (11), A549 (a human lung adenocarcinoma
epithelial cell line) (24), and HeLa (a cervical cancer cell line) were obtained
from the American Type Culture Collection. These cell lines were used in this
study and were maintained in Dulbecco’s minimal essential medium (DMEM)
containing 10% fetal bovine serum (FBS) in a humidified incubator with 5%
CO2. No antibiotics were used in the preparation of the medium.
HEp-2 cell assay. The HEp-2 cell attachment assay was carried out as de-
scribed previously (11), except that confluent monolayers were used instead of
cells grown to 50 to 80% confluence unless otherwise specified. HEp-2 cells were
grown in Lab-Tek II (Nunc, Rochester, NY) chambered slides and were incu-
bated in the presence of antibiotics or the appropriate controls for 4, 8, 16, 18,
and 24 h. At the end of the antibiotic incubation period, chambers were washed
three times with PBS (phosphate-buffered saline, pH 7.4) prior to the addition of
EAEC (7  106 to 1  107 bacteria in 1 ml DMEM, 10% FBS, and 1%
D-mannose) (2, 9) that had been cultured at 37°C overnight in Trypticase soy
broth (Difco, Lawrence, KS) with 1% D-mannose (Sigma, St. Louis, MO). After
a 3-h incubation at 37°C, the attachment of E. coli O42 to epithelial cells was
visualized microscopically following Wright-Giemsa staining (Protocol Hema 3;
Fisher Diagnostics, Middletown, VA) using an Olympus BX60 inverted micro-
scope attached to an Olympus C-5060 digital camera.
Quantification of bacterial adherence and internalization. HEp-2, HCT-8,
A459, or HeLa cells were grown to confluence in 24-well plates (Corning Inc.,
Corning, NY) and incubated with the respective antibiotics or controls. Twenty-
four hours later, the supernatants were removed, and the wells were washed
gently three times with 1 ml PBS prior to the addition of either EAEC strain O42
(2, 9) or S. sonnei (7 106 to 1 107 in 1 ml DMEM, 10% FBS, 1% D-mannose)
grown at 37°C overnight in Trypticase soy broth with 1% D-mannose, or B.
anthracis spores (4.8  105) prepared from Sterne strain 7702 in phage assay
(PA) medium as described previously (10, 24, 25).
For the quantification of bacterial adherence, EAEC O42 was incubated in the
presence of the respective antibiotic-pretreated cell lines, and S. sonnei was
incubated in the presence of antibiotic-pretreated HeLa cells, in 24-well plates
for 3 h at 37°C. Following this incubation, the supernatants were removed, and
the wells were washed three times with 1 ml sterile PBS. Distilled water (1 ml)
was then added to the wells, and the cells were removed by pipetting, diluted in
sterile PBS, and plated on Luria-Bertani (LB) agar plates for quantification by
counting of CFU 16 h later. For B. anthracis attachment, A549 cells were grown
to confluence in 24-well tissue culture plates and pretreated for 24 h with
antibiotics as described above. The cells were washed three times with PBS to
remove antibiotics and were then infected with Sterne strain 7702 spores for 1 h
at 37°C in a humidified chamber with 5% CO2. Unbound spores were removed
by three washes with PBS, and the A549 cells were removed and plated on LB
agar plates as described above for CFU determinations.
For the internalization assays, S. sonnei or B. anthracis was incubated with
antibiotic-treated HeLa or A549 cells, respectively, as described above. After the
bacteria were incubated with the respective cell lines and the wells were washed,
the epithelial cells were further incubated with a medium containing gentamicin
(100 g/ml) for 1 h to kill noninternalized bacteria, washed with PBS, lysed in
distilled water, and plated for quantification as described above.
In one experiment, the number of EAEC bacteria in the supernatants follow-
ing the 3-h incubation with HEp-2 cells treated with various antibiotics or
controls was determined. Supernatants were collected, and the wells were
washed three times with 200 l sterile PBS. The PBS washes and the superna-
tants were combined, centrifuged, and resuspended in 1 ml sterile PBS; the
suspension was then serially diluted and plated on LB agar plates for quantifi-
cation as described above.
The CFU data are means  standard errors (SE) from triplicate wells for
bacteria that adhered or were internalized and are expressed as percentages of
the total bacteria added to the respective treatment wells. Statistical differences
in bacterial counts were determined using Student’s t test.
Antibiotics. Rifaximin (Salix Pharmaceuticals Inc., Morrisville, NC), rifampin
(Sigma), doxycycline (Sigma), or gentamicin (Sigma) were tested in attachment/
internalization assays. Rifaximin was dissolved in acetone and rifampin, and
doxycycline and gentamicin were dissolved in water (1-g/l stocks of each were
prepared). Antibiotics were prepared fresh at the start of each experiment.
Antibiotics and acetone were sterile filtered with a 0.22-M-pore-size syringe
filter before use. Antibiotics were incubated with HEp-2 cells for various times at
8, 32, or 64 g/ml and with HCT-8, A549, or HeLa cells for 24 h at 32 or 64
g/ml. Acetone was administered at a volume equivalent to the volume used to
deliver each respective antibiotic concentration as a negative control. The con-
centrations tested were based on the MICs of rifaximin and rifampin. The
highest dose of rifaximin selected (64 g/ml) corresponded to the MIC50 previ-
ously established for EAEC in our laboratory (14).
Supernatant dialysis. HEp-2 cells were cultured in T-175 flasks as described
above. When the cells reached confluence, the medium was removed and re-
placed with fresh medium containing either no antibiotics, rifaximin, rifampin,
doxycycline, or acetone (64 g/ml or acetone at the same volume used to deliver
the antibiotics). After 24 h, the medium was collected, loaded into regenerated
cellulose dialysis tubing (cutoff, 6 to 8 kDa; Spectra/Por, Rancho Domiguez,
CA), and dialyzed against 4 liters of PBS changed four times. Each dialysis step
lasted at least 6 h and was carried out at 4°C. Dialyzed supernatants were either
used immediately in adherence assays or stored at 20°C until use.
The effect of supernatants on EAEC adherence was determined by mixing
EAEC with the dialyzed media from the different antibiotic (or control) treat-
ment groups and adding the bacteria to HEp-2 cells cultured in chambered slides
or to chambered slides with no HEp-2 cells. Adherence was visualized micro-
scopically as described above.
Cytokine arrays. HEp-2 cells were plated on chambered slides and grown to
confluence. The medium was replaced with fresh medium containing either
antibiotics (64 g/ml), a diluent control (64 l) (acetone), or medium with no
antibiotics. Supernatants were collected 24 h later and were used to probe a
cytokine array membrane (Panomics, Fremont, CA) that supported the detec-
tion of Apo/Fas, cytotoxic T-lymphocyte-associated antigen (CTLA), eotaxin,
granulocyte-monocyte colony-stimulating factor (GM-CSF), epidermal growth
factor (EGF), gamma interferon (IFN-)-inducible protein 10 (IP-10), leptin,
monocyte inflammatory protein 1 (MIP1), MIP1	, MIP4, MIP5, matrix met-
alloprotease 3 (MMP3), RANTES (regulated on activation, normal T-expressed
and secreted), transforming growth factor 	 (TGF-	), IFN-, tumor necrosis
factor alpha (TNF-), TNF receptor I (TNFRI), TNFRII, intracellular adhesion
molecule 1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1), vascular
endothelial growth factor (VEGF), interleukin-1 (IL-1), IL-1	, IL-R, IL-2,
IL-3, IL-4, IL-5, IL-6, IL-6R, IL-7, IL-8, IL-10, IL-12 (p40), IL-15, and IL-17 as
described by the manufacturer. The presence of the respective supernatant
proteins was visualized by exposing and then developing Amersham Hyperfilm
ECL (GE Healthcare, Buckinghamshire, United Kingdom) film. Blots probed
with the respective supernatants were analyzed at the same time and developed
simultaneously on the same Hyperfilm.
RESULTS
Effect of rifaximin on EAEC adherence. The effect of rifaxi-
min on bacterial attachment was first examined using the stan-
dard HEp-2 cell adherence assay commonly carried out to
phenotypically define EAEC isolates based on their stacked-
brick adherence pattern (8, 15). HEp-2 cells were grown to
confluence and were then incubated with rifaximin, rifampin,
doxycycline, or acetone. After 24 h, the wells were washed
prior to the addition of the EAEC strain O42. EAEC O42
adhered in the traditional stacked-brick formation to un-
treated HEp-2 cells (Fig. 1A) or HEp-2 cells treated with
rifampin, doxycycline, or acetone (data not shown); however,
the level of adherence to rifaximin-pretreated HEp-2 cells was
greatly reduced (Fig. 1B). These effects were time and concen-
tration dependent (data not shown); however, since pretreat-
ment with 64 g/ml rifaximin for 24 h had the greatest effects
on bacterial attachment, this dose was used in subsequent
experiments.
EAEC adherence to HEp-2 cells following pretreatment
with the various antibiotics or controls was quantified. The
level of EAEC adherence to rifaximin-pretreated cells was
significantly lower than the level of adherence to untreated
cells or to cells treated with either rifampin, acetone (Fig. 1C),
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FIG. 1. EAEC attachment following pretreatment with rifaximin. (A) Untreated HEp-2 cells incubated with 7  106 EAEC bacteria. The
arrows indicate EAEC attaching to the HEp-2 cell and slide surfaces (magnification, 100). (B) HEp-2 cells pretreated for 24 h with rifaximin (32
g/ml), washed, and then incubated with 7  106 EAEC bacteria (magnification, 100). The arrow indicates cells attaching to the slide surface
and leading edge of HEp-2 cells. (C) Concentrations of EAEC in the supernatant or attached to the cell surface. HEp-2 cells grown to confluence
in 24-well plates were pretreated with rifaximin, acetone, or rifampin, or were left untreated, for 24 h; then they were washed as described in
Materials and Methods and were incubated with EAEC for 3 h in triplicate. To determine the CFU of EAEC in the supernatant, supernatants
from respective wells were collected, and the wells were washed three times with PBS (200 l each time). The supernatants and the washes were
combined, centrifuged, resuspended in 1 ml PBS, serially diluted, and plated onto LB agar plates. To determine the number of EAEC bacteria
attached, HEp-2 cells were trypsinized, washed, and plated onto LB plates as described above. The data are expressed as mean percentages of the
total bacteria added to the wells that were found in the supernatant or attached to the cell surface. Error bars, SE. CFU counts in the supernatants
or cell fractions of triplicate wells demonstrated reduced EAEC adherence to HEp-2 cells pretreated with rifaximin. †, P  0.05 by an unpaired
Student t test.
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or doxycycline (not shown). No differences in bacterial counts
were observed in the supernatants (Fig. 1C).
To determine if the observed reduction in EAEC adherence
following rifaximin pretreatment of HEp-2 cells extended to
other cell types or bacteria, we examined EAEC O42 adher-
ence to three additional cell lines. We examined the effects of
rifaximin pretreatment on adherence and internalization using
two vastly distinct pathogens: B. anthracis and S. sonnei.
EAEC adherence to HEp-2, HCT-8, A549, and HeLa cells
was measured by carrying out adherence assays as described
above. The respective cell lines were grown to confluence in
24-well plates, and fresh medium containing no antibiotics or
64 g of either rifaximin, rifampin, doxycycline, or acetone (64
l) was added for 24 h. Rifaximin pretreatment significantly
reduced EAEC adherence to HEp-2, HeLa, and A549 cells.
Slightly fewer bacteria adhered to rifaximin-pretreated HCT-8
cells, but this difference was not significant, suggesting differ-
ences in cellular susceptibility to rifaximin (Fig. 2).
We measured the adherence and internalization of B. an-
thracis and S. sonnei to determine if rifaximin pretreatment
affected these processes in different bacteria. B. anthracis is a
Gram-positive spore-forming bacteria that is the causative
agent of anthrax. Humans become infected via spore entry into
the lungs or gut or via skin abrasions; infections can result in
sepsis and secondary manifestations, including meningitis and
potentially death. Recently, the laboratory of Y. Xu estab-
lished a model of adherence and internalization (using the
gentamicin protection assay) for B. anthracis Sterne strain 7702
in A549 lung epithelial cells that was modified in this study to
examine the role of rifaximin in these processes (24, 25). S.
sonnei is a Gram-negative member of the family Enterobacte-
riaceae that causes disease in humans by invading and repli-
cating in cells lining the colonic mucosa. Of the four Shigella
species, S. sonnei is the most common cause of shigellosis in
developed countries (22).
Following incubations with the respective antibiotics (or
controls), significant reductions in both the adherence and the
internalization of B. anthracis were observed in rifaximin-pre-
treated A549 cells compared to those for the other treatment
groups, including an internal gentamicin-only treatment group
(Fig. 3A and B). In contrast, rifaximin pretreatment of HeLa
cells had no effect on S. sonnei attachment or internalization
compared to those for the other treatment groups under the
conditions examined (Fig. 3C and D).
Effect of HEp-2 supernatants on EAEC adherence. Because
EAEC adherence to HEp-2 cells in the stacked-brick for-
mation is the gold standard for defining EAEC isolates, we
next attempted to determine if the observed reduction in
EAEC adherence following rifaximin pretreatment was due
to rifaximin-mediated alterations in HEp-2 cell physiology
that could be conferred via the supernatants of treated cells.
To this end, HEp-2 cells were grown in a medium containing
64 g/ml of either rifaximin, rifampin, or doxycycline (or
acetone [64 l/ml]) for 24 h. Supernatants were then col-
lected and dialyzed extensively using 6- to 8-kDa-cutoff di-
alysis tubing to remove any trace of the antibiotics used in
the respective treatment groups. This ensured that when the
dialyzed media corresponding to the respective antibiotic
treatment groups were mixed with EAEC in order to exam-
ine the effects of the supernatants on adherence, any
changes observed would not be due to antibiotics in the
medium. After dialysis, the supernatants were sterile filtered
and mixed with EAEC, and adherence to chambered slides
with or without HEp-2 cells (50% confluent) was examined.
After a 3-h incubation, the slides were washed and stained
as described above. EAEC that was mixed with dialyzed
supernatants from HEp-2 cells only, i.e., with no antibiotic
treatment (Fig. 4A and C), or with dialyzed supernatants
from HEp-2 cells pretreated with either rifampin (Fig. 4B),
doxycycline, or acetone (data not shown), adhered to cham-
bers independently of the presence of HEp-2 cells (Fig. 4A
and B, with HEp-2 cells; Fig. 4C, without HEp-2 cells).
EAEC mixed with PBS and added directly to chambers for
3 h adhered in a fashion indistinguishable from the adher-
FIG. 2. Rifaximin pretreatment reduced EAEC binding to epithelial cells. Confluent HEp-2, HeLa, A549, or HCT-8 cells were cultured for 24 h
either in medium only or in medium containing 64 g/ml of either rifaximin, rifampin, acetone (64 l), or doxycycline in triplicate. The wells were
washed, and 1  107 EAEC bacteria were added and incubated for 3 h. Then the wells were washed three times with 1 ml of PBS (each wash),
and the cells were lysed by addition of 1 ml of sterile distilled water. Serial dilutions were then made in sterile PBS and plated onto LB agar plates
to determine the number of CFU per well. The data are expressed as the percentage of the total number of bacteria added to the wells that adhered
to the cells. P values, determined by an unpaired Student t test, were 0.0001 (†) and 0.03 (§).
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ence pattern visible in Fig. 4A to C (data not shown), sug-
gesting that the bacterial adherence pattern was not affected
by the medium/buffer used in the adherence assay. In con-
trast, EAEC that was mixed with dialyzed supernatants from
rifaximin-treated HEp-2 cells adhered poorly to chambered
wells in the presence or absence of HEp-2 cells (Fig. 4D
and E, respectively).
Cytokine arrays. Since the supernatants collected from ri-
faximin-treated HEp-2 cells had the capacity to confer changes
in EAEC adherence, we defined the cytokine profiles of the
respective supernatants incubated for 24 h alone (Fig. 5A) or
pretreated (24 h) with either rifampin (Fig. 5B) or rifaximin
(Fig. 4C). GM-CSF, MIP4, MIP5, MMP3, RANTES, TGF-	,
IFN-, TNFRI, TNFRII, VCAM-1, VEGF, IL-4, IL-6, IL-8,
IL-12 (p40), and IL-15 could be found in the supernatants of
untreated (Fig. 5A), doxycycline-treated, or acetone-treated
(data not shown) cells. Rifampin-treated cell supernatants had
the same profile, except that MIP5 was not detected (Fig. 5B).
In contrast, supernatants analyzed from HEp-2 cells cultured
in the presence of rifaximin contained detectable levels of
RANTES and IL-4 only (Fig. 5C).
DISCUSSION
Rifaximin is a poorly absorbed antibiotic that effectively
treats traveler’s diarrhea and has been used in the treatment of
Clostridium difficile-diarrhea (3, 4, 6, 10, 16). How rifaximin
treatment ameliorates disease symptoms remains poorly un-
derstood. Although it has been shown to have both bactericidal
and bacteriostatic properties that account for some of the
antimicrobial benefits derived from rifaximin treatment, one of
the most intriguing aspects of this drug is that it can shorten
the duration of bacterial diarrhea without invariably eradicat-
ing enteropathogen infections and with minimal effects on the
colonic bacterial flora (1), suggesting additional mechanisms of
action. Although infections with different pathogens can result
in diarrheal disease symptoms, the pathophysiological mecha-
nisms employed by these pathogens can differ. Even among
diarrheagenic E. coli strains, the nature of the microbe-mucosa
interactions differs greatly, e.g., for enterotoxigenic, enterohe-
morrhagic, enteropathogenic, enteroinvasive, and enteroag-
gregative E. coli (21). Alterations in the interactions of the host
cells with the pathogen could affect the disease presentation
caused by these organisms differently, i.e., rifaximin may alter
FIG. 3. Effects of rifaximin pretreatment on the adherence and internalization of B. anthracis and S. sonnei. Graphs show the adherence (A and
C) or internalization (B and D) of B. anthracis (A and B) or S. sonnei (C and D). B. anthracis spores (4.8  105) or S. sonnei bacteria (1  107)
were cocultured in wells of 24-well plates containing either A549 or HeLa cells, respectively. For adherence assays, the respective bacteria were
incubated for 1 h; the wells were washed; and the cells were plated onto LB agar plates. For internalization, an additional 1-h incubation with
gentamicin (100 g/ml) was carried out to kill any noninternalized bacteria. The wells were then washed, and the cells were plated onto LB agar
plates. The data are expressed as the mean percentages of the total cells added that adhered or were internalized. Error bars, SE. The experiment
was repeated twice and with similar results. †, P  0.002 by an unpaired Student t test.
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FIG. 4. Effects of dialyzed supernatants on EAEC adherence. EAEC adherence was assessed by adding 750 l of an EAEC solution (7 106 bacteria/ml)
mixed with 750l of either dialyzed conditioned medium only (A and C), dialyzed rifampin-conditioned medium (B), or dialyzed rifaximin-conditioned medium
(D and E). EAEC adherence was monitored in the presence (A, B, and D) or absence (C and E) of HEp-2 cells. After a 3-h incubation, the chambers were
washed and examined microscopically (magnification, 40) following Wright-Giemsa staining. These experiments demonstrated that a factor (or the lack
thereof) in the supernatant of rifaximin-treated cells affected EAEC adherence. This experiment was repeated twice with similar results.
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FIG. 5. Supernatant cytokine profile analysis. Supernatants from HEp-2 cells cultured for 24 h without antibiotics (A), in the presence of
rifampin (B), or in the presence of rifaximin (C) were analyzed using a Panomics cytokine array. Each membrane array is designed to detect as
many as 36 different cytokines (indicated to the right) in duplicate, together with positive and negative internal controls. The blots shown were
incubated with the respective supernatants at the same time and were developed on the same film simultaneously. Supernatants from HEp-2 cells
treated with doxycycline or acetone were also analyzed (data not shown). This experiment was carried out three times with similar results,
demonstrating that rifaximin reduced the expression of various proinflammatory cytokines.
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the bacterial adherence of organisms that share adherence or
internalization strategies. Reduced mucosal attachment may at
least partially explain the beneficial effects of rifaximin when
used to prevent traveler’s diarrhea caused by diarrheagenic E.
coli strains (8). The observation that rifaximin is more active
against organisms that require interaction with the gut mucosa
may further explain why nonpathogenic or normal colonic flora
typically not “associated” with the intestinal lining are less
affected by this drug and why symptoms associated with EAEC
infections are ameliorated without necessarily eliminating the
pathogen (1).
In this report we demonstrated that rifaximin pretreatment
decreased bacterial adherence to HEp-2 cells without affecting
EAEC viability, since equal numbers of bacteria were recov-
erable from the supernatants of all treatment groups. In con-
trast, the number of bacteria that adhered to confluent HEp-2
cells pretreated with rifaximin was significantly lower than the
number of EAEC bacteria recoverable from cells treated with
control antibiotics or left untreated. The fact that there was not
an increase in the number of EAEC bacteria in the superna-
tants of rifaximin-treated cells (since fewer bacteria were re-
covered from the cell fraction) can be explained as a function
of the EAEC cell density added to the cell cultures, i.e., the
EAEC bacteria added for the 3-h incubation were grown over-
night and were in stationary phase at the time of incubation.
During the short time of the adherence assay, significant dif-
ferences in bacterial growth in the supernatants were not likely
to be observed.
Although EAEC adherence to HEp-2, A549, and HeLa cells
was significantly reduced following rifaximin pretreatment, lit-
tle or no change in adherence to HCT-8 cells pretreated with
rifaximin was observed, suggesting that different cell lines re-
spond differently to, or have different thresholds of sensitivity
to, this compound. Although the nature of the cellular changes
affecting EAEC adherence remains undefined, the differences
in the adherence and internalization of B. anthracis (but not in
those of S. sonnei) due to rifaximin pretreatment suggested
that specific changes to cellular physiology were induced by
rifaximin, since these bacteria utilize significantly different ad-
herence/internalization mechanisms. Although we are not sug-
gesting that rifaximin be used for the treatment of anthrax, we
can utilize the B. anthracis model to better understand how this
bacterium adheres to and becomes internalized by epithelial
cells, since the mechanisms that mediate these processes are
independent of each other and not fully defined (24, 25). Fur-
thermore, understanding of these processes can be used in the
rational design of drugs that can mimic the effects conferred by
rifaximin for the treatment of infections caused by this or
similar pathogens.
The lack of effect of rifaximin pretreatment on S. sonnei
adherence and internalization does contradict a recent study
that established the use of rifaximin for the treatment of shig-
ellosis (27), since the data presented in the present report
examine only the effect of rifaximin on epithelial cells and do
not address its antibiotic properties or its use in the treatment
of shigellosis.
Since B. anthracis and S. sonnei utilize vastly different mech-
anisms of adherence and internalization (zipper versus trigger,
respectively) (3, 24, 25), we can speculate as to the potential
cellular compartments affected by rifaximin, since one bacte-
rium was affected and the other was not. Specifically, S. sonnei
utilizes a sophisticated type III secretory system involving var-
ious host cell-signaling molecules that affect the cytoskeleton.
B. anthracis internalization also involves various host cell sec-
ondary messengers and modifications to the cytoskeleton for
internalization; however, various differences exist. For exam-
ple, B. anthracis internalization does not require the mem-
brane-cytoskeletal protein vinculin for internalization (Y. Xu,
unpublished data), but this component does play a critical role
in Shigella internalization by anchoring adhesion complexes to
the actin cytoskeleton (3).
Since rifaximin is related to ansamycins (e.g., rifampin, ri-
fabutin, rifalazil), which have been reported to have anti-in-
flammatory and immunosuppressive properties, and because
several studies have suggested that rifaximin had effects on
mammalian cell function, we chose to examine the cytokine
profile in the supernatants of rifaximin-treated (and control)
HEp-2 cells (16, 17). Defining the cytokine production profile
was a rapid means of detecting potential changes in host cell
physiology, in addition to characterizing this response in epi-
thelial cells. This analysis is different from those of previous
studies examining the effects of ansamycins on immune cell
function and cytokine production. Specific to rifaximin, how-
ever, is a previous finding that humans with uncomplicated
diverticular disease treated with rifaximin showed altered ex-
pression patterns of adhesion molecules associated with T-cell
homing to the mucosa (2). A second study examined the role
of rifaximin, alone or in the presence of a rifaximin-resistant
probiotic Bifidobacterium infantis strain, on cytokine produc-
tion by peripheral blood mononuclear cells (PBMCs) or the
intestinal enterocytic HT29 cell line. This study by Vitali et al.
demonstrated that rifaximin had the capacity alone (or in the
presence of B. infantis) to increase PBMC production of IL-1	,
IL-6, and TNF- and that the production of IL-8 by HT29 cells
was increased if rifaximin was administered alone (28). IL-8
production by HT29 cells was significantly reduced if rifaximin
was administered with B. infantis (28). The last observation is
of interest because IL-8 has been shown to play a role in the
severity of EAEC infections (11), suggesting that IL-8 down-
regulation may ameliorate disease-related symptoms; however,
the Vitali study showed that rifaximin alone increases IL-8
production, and in the present report, rifaximin downregulated
IL-8 (and most cytokines detected in the supernatants of un-
treated and control antibiotic-treated HEp-2 cells). The two
primary differences between our study and that of Vitali et al.
were the cell type used (HEp-2 versus HT29 cells) and the dose
of rifaximin (64 versus 100 g). Furthermore, a caveat to our
study is that we were not able to assess the effect of rifaximin
plus EAEC on cytokine production or to determine the effects
on the adherence of bacteria added to HEp-2 cells first and
then treated with rifaximin, since we do not at this time have a
rifaximin-resistant EAEC isolate with which to carry out these
experiments.
Although we report here that rifaximin pretreatment signif-
icantly affected the natural cytokine expression profile of
HEp-2 cells, we cannot from these data determine whether the
downregulation of cytokines (or the upregulation of a yet un-
defined inhibitory factor) following rifaximin treatment was
responsible for the reduced adhesion observed. The mecha-
nism(s) resulting in altered EAEC adherence likely involved
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direct rifaximin-mediated alterations to the HEp-2 cells, which
in turn affected the bacterial adherence pattern (directly, indi-
rectly, or both). Furthermore, the observation that the effects
were time and concentration dependent suggested that a ri-
faximin-mediated process was altering cellular parameters im-
portant to EAEC adherence. The likelihood that the presence
or absence of a factor in the supernatant directly affected
bacterial attachment was observed when bacteria were mixed
with dialyzed supernatants obtained from HEp-2 cells treated
with different antibiotics. Only dialyzed supernatants from ri-
faximin-treated cells altered bacterial attachment to HEp-2
cells not previously treated with rifaximin. Adherence was also
reduced in the absence of HEp-2 cells, i.e., with glass only,
suggesting that factors (or a lack thereof) in the supernatant
were interacting with EAEC directly, thereby changing the
adherence potential of the bacteria.
The data presented in this report suggested that rifaximin-
mediated changes to various epithelial cell types reduced
EAEC attachment by biologically altering the host cell. These
effects extend to B. anthracis adherence and internalization but
not to S. sonnei, suggesting that rifaximin-mediated changes in
cell physiology did not have an effect on all bacteria. These
observations suggested that significant functional differences
between rifaximin and its cousin rifampin exist. Experiments
designed to identify the factor(s) associated with rifaximin al-
teration of epithelial cell binding are currently under way.
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